CD BioSciences is a CRO company comprised of scientists, bioinformaticians, oncologists, and so on. Our team works closely and communicates actively to achieve our common goals of helping researchers and professionals understand pancreatic cancer (PC) biology, develop new PC biomarkers, and explore new PC therapeutics and protocols.
PC clinical trials
Surgical resection, radiation therapy, ablative therapy, and chemotherapy are the common conventional treatments for PC. There has been little progress in the treatment of PC and it remains the only major cancer type with a 5-year survival rate of less than 10%. PC clinical trials are research studies that offer promising new cancer treatments for patients that are not yet readily available. Clinical trials provide a reliable way to assess the effectiveness of newly discovered drugs and technologies versus those currently in use, they play a key role in promoting cancer prevention and treatment.
Goals of PC clinical trials and research
PC clinical trials and research have been used to evaluate the safety and effectiveness of new treatment approaches for PC. At present, there are some of the major goals of PC clinical trials and research, but not limited to them.
- Exploring new techniques to reduce surgical complications
- Research on biomarkers (proteins and genes) that can help us achieve early detection, for example, to distinguish between benign (non-cancerous) lesions and precancerous lesions of the pancreas
- Investigation of personalized treatment protocols relying on pancreatic stem cells
- Working to develop targeted treatments
- Exploring novel immunotherapy approaches using the immune system against PC.
PC clinical trial targets
PC is a recalcitrant and aggressive disease characterized by high incidence and poor prognosis. Scientists and physicians are studying a range of different proteins, pathways, and platforms to develop new PC treatments.
- Targeted antibodies
Targeted antibodies are proteins produced by the immune system that can be tailored to target specific markers on cancer cells to disrupt cancer activity, especially their unrestricted growth. Bispecific T-cell engaging antibodies (BiTEs) can help the immune system respond faster and more efficiently by binding cancer cells and T cells. Antibody-drug conjugates (ADCs) are equipped with anti-cancer drugs, resulting in the more efficient delivery of drugs to the tumor. Here, we list some of the antibody targets that are evaluated in PC clinical trials.
- Cancer vaccines
Cancer vaccines are designed to trigger an immune response against tumor-specific or tumor-associated antigens, helping the immune system recognize and eliminate cancer cells that carry these antigens. Cancer vaccines can be made from a variety of components, such as cells, proteins, DNA, and viruses. Cancer vaccines can be divided into three types, including preventive cancer vaccines, therapeutic cancer vaccines, and personalized neoantigen vaccines. Here, we list some of the cancer vaccine targets evaluated in PC clinical trials.
- Adoptive cell therapy
In cancer therapy, immune cells from patients are expanded or modified, and then reintroduces to the patients to help the immune system fight cancer. In chimeric antigen receptor (CAR) T-cell therapy, modified T cells are grown in large numbers in the laboratory and then given back to the patient to help the body target cancer cells and kill them. Types of adoptive cell therapy include CAR T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and natural killer cell (NK) therapy. Here, we list some of the cell-based immunotherapy targets evaluated in PC clinical trials.
- Immunomodulators
Immunomodulators are a type of immunotherapy that enhances the body's immune response to cancer. There are some immunomodulator targets under-evaluated in PC clinical trials, including CD40, CSF1/CSF1R, CD73, and so on.
- Oncolytic virus (OV) therapy
OV therapy uses viruses that are often modified in order to infect tumor cells and cause them to self-destruct. Due to their unique characteristics in terms of replication and anti-tumor immune response, OVs are considered as a new option for cancer therapy, including PC. There are some virus platforms used in PC clinical trials, including adenovirus, herpes simplex virus (HSV), parvovirus, and so on.
| PC Clinical Trial Targets | ||||
|---|---|---|---|---|
| Targeted Antibodies | Cancer Vaccines | Adoptive Cell Therapy | Immunomodulators | Oncolytic Virus Therapy |
| EGFR | CEA | CEA | CD40 | Adenovirus |
| HER2 | Mesothelin | Epstein-Barr Virus (EBV)-related antigens | CD73 or A2AR | Herpes simplex virus (HSV) |
| Mesothelin | MUC-1 | EGFR | CSF1/CSF1R | Parvovirus |
| PDGFRα | P53 | Mesothelin | CTLA-4 | Reovirus |
| VEGF/VEGF-R | Personalized neoantigens | MUC1 | CXCR4 | Vaccinia virus |
| IGF-1/ IGF-2 | Ras | PSCA | IDO | |
| IGF-1R/ErbB3 | Survivin | ROR1 | IL-2/IL-2R | |
| Telomerase | WT1 | PD-1/PD-L1 | ||
| Tumor-associated antigens (TAAs) | STAT3 | |||
| WT1 | Toll-like receptors (TLRs) | |||
How can we help you?
CD BioSciences is committed to providing our customers with optimal customized services and solutions to meet the specific needs of their projects. Our services include but are not limited to the following list:
- Further exploration of the molecular mechanisms underlying the initiation, progression, and maintenance of PC.
- Discovery of new molecular targets driving PC initiation, progression, and metastasis that can be used as new therapeutic or treatment targets.
- Preclinical evaluation of new anticancer drugs and strategies for PC.
- Screening and identification of new validated biomarkers for early detection of PC.
In order to get more details about our services, please contact us. We've got everything covered for your needs.
Reference
- Lai, Eleonora, et al. "New therapeutic targets in pancreatic cancer." Cancer treatment reviews 81 (2019): 101926.